NuGen Medical Devices Inc. (TSXV: NGMD), a developer of needle-free drug-delivery systems, has signed a non-binding letter of intent to acquire Sol-Millennium Canada Inc., a Canadian distributor of medical devices and healthcare products.
Under the proposed transaction, NuGen would acquire all outstanding shares of Sol-Millennium Canada from its sole shareholder, Sol-Millennium Medical HK Limited. If completed on the terms currently contemplated, Sol-Millennium Medical HK would own approximately 65% of NuGen’s post-transaction common shares, while existing NuGen shareholders would collectively hold approximately 35%. That calculation does not assume conversion of any outstanding NuGen convertible securities.
Sol-Millennium Canada has also agreed to provide NuGen with a C$1.3 million secured bridge loan, subject to TSX Venture Exchange approval. The proposed financing includes C$500,000 following execution of a loan agreement and another C$800,000 upon execution of a definitive acquisition agreement.
The loan would be secured against NuGen’s assets, carry an annual interest rate of 6%, and mature five years after the initial advance.
The parties are currently conducting due diligence. NuGen must also negotiate the conversion, settlement, deferral or other treatment of certain outstanding debt obligations on terms acceptable to the parties before the transaction can proceed.
Sol-Millennium Canada distributes medical devices including needles, syringes, blood collection products, diabetes-care products, safety-engineered devices and personal protective equipment to healthcare providers across Canada. NuGen’s principal product is InsuJet, a needle-free insulin delivery system approved in 42 countries.
The two companies had an existing commercial connection before the proposed transaction. In a January 2026 corporate update, NuGen said it was supporting Sol-Millennium Medical Group’s participation at Pharmapack Europe. At the time, NuGen CEO Liang Lin said, “Our progress in 2025 reflects the disciplined work of our teams across R&D, clinical development, and global market engagement.”
The proposed transaction comes as NuGen continues to require outside financing. As of March 31, 2026, the company reported C$1.78 million in cash, C$3.70 million in current liabilities and an accumulated deficit of C$42.45 million. NuGen recorded a net loss of approximately C$1.60 million for the quarter.
The company’s filings state that material uncertainty exists regarding its ability to continue as a going concern and that additional financing will be required to support future operations and expansion.
Upcoming Catalysts
NuGen and Sol-Millennium are conducting due diligence and expect to negotiate a definitive agreement if that process is completed satisfactorily.
Other items to watch include TSXV approval of the C$1.3 million bridge loan, arrangements regarding NuGen’s outstanding debt obligations, board and regulatory approvals, and any definitive transaction agreement. NuGen has not announced a closing date, and the non-binding LOI does not guarantee that the acquisition will be completed.
Sources
- NuGen Announces Non-Binding LOI to Acquire Sol-Millennium Canada — August 6, 2026, via Newsfile Corp.
- NuGen Medical Devices Q1 2026 Management’s Discussion and Analysis — June 1, 2026, filed through SEDAR+
- NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress — January 16, 2026
Editorial Disclosure
This article is based entirely on publicly available information including press releases, SEDAR filings, and publicly available news sources. Securities discussed or referenced include NuGen Medical Devices Inc. (TSXV: NGMD). Next Gen Tech Stocks has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party for this specific article. Next Gen Tech Stocks may have current or past paid business relationships with other companies, which does not influence the content or conclusions of this article. No staff member or principal of Next Gen Tech Stocks holds a position in any security mentioned at the time of publication.
Sources include NuGen Medical Devices’ August 6, 2026 press release distributed through Newsfile Corp.; the company’s Management’s Discussion and Analysis for the three-month period ended March 31, 2026; and its January 16, 2026 corporate update.
The proposed acquisition remains subject to due diligence, negotiation and execution of a definitive agreement, board and regulatory approvals, and acceptable arrangements regarding certain NuGen debt obligations. The letter of intent is non-binding, and there is no assurance that the proposed transaction will be completed.
If completed on the currently proposed terms, Sol-Millennium Medical HK Limited would hold approximately 65% of NuGen’s post-transaction common shares, while existing NuGen shareholders would hold approximately 35%, excluding potential conversion of outstanding convertible securities.
As of March 31, 2026, NuGen reported approximately C$1.78 million in cash, C$3.70 million in current liabilities and a C$42.45 million accumulated deficit. The company has disclosed material uncertainty that may cast significant doubt on its ability to continue as a going concern and expects to require additional financing for future operations and expansion.
These are speculative investments carrying significant risk including potential total loss of capital. Coverage on Next Gen Tech Stocks is provided for informational and educational purposes only. Next Gen Tech Stocks is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
